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Tuberculosis (TB), one of the most wide-
spread infectious diseases, is the leading cause of
death due to a single infectious agent among
adults in the world. Mycobacterium tuberculosis
is the most common cause of human TB, but an
unknown proportion of cases are due to M. bovis
(1). In industrialized countries, animal TB
control and elimination programs, together with
milk pasteurization, have drastically reduced the
incidence of disease caused by M. bovis in both
cattle and humans. In developing countries,
however, animal TB is widely distributed, control
measures are not applied or are applied
sporadically, and pasteurization is rarely prac-
ticed. The direct correlation between M. bovis
infection in cattle and disease in the human
population has been well documented in
industrialized countries. Whereas little informa-
tion is available from developing countries (2,3),
risk factors for M. bovis in both animals and
humans are present in the tropics.
TB is a major opportunistic infection in HIV-
infected persons (4). The vast majority of people
carrying this dual infection live in developing
countries; however, dual HIV and M. bovis
infection has been reported in industrialized
countries (5-11). The epidemic of HIV infection in
developing countries, particularly countries in
which  M. bovis infection is present in animals and
the conditions favor zoonotic transmission, could
make zoonotic TB a serious public health threat
to persons at risk (3,12-14).
We summarize available epidemiologic infor-
mation on TB and zoonotic TB, examine risk
factors that can influence the occurrence of
zoonotic TB in developing countries, and describe
the most recent TB activities of the World Health
Organization (WHO) (15-18).
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Human TB: Global Situation and Trends
The global incidence of TB is greatly
underestimated. In 1995, 3.3 million cases were
reported to the Global Tuberculosis Programme
of WHO, whereas a more likely number is 8.8
million. Of the reported cases, 62% occurred in
the Southeast Asian and Western Pacific regions,
16% in sub-Saharan Africa, and 7% to 8% in each
of the regions of the Americas, Eastern
Mediterranean, and Europe. Many countries,
especially those with few resources, are unable to
report all TB cases because of difficulties in
identifying suspected cases, establishing a
diagnosis, and recording and reporting cases.
In 1995, an estimated 8.8 million new TB
cases occurred—5.5 million (62%) in the
Southeast Asian and Western Pacific regions and
1.5 million (17%) in sub-Saharan Africa. The
annual global incidence is predicted to increase to
10.2 million by the year 2000, an increase of
36% from 1990. Southeast Asia, Western
Pacific regions, and sub-Saharan Africa will
account for 81% of these new cases (Table 1).
For 1990 to 1999, in the absence of effective
control, global TB incidence and deaths will
reach 88 million and 30 million, respectively
(19); 70% of the new cases will occur in patients
15 to 59 years of age, the most economically
productive segment of the population.
As a result of the HIV epidemic, the crude
incidence rate of TB is expected to increase in
sub-Saharan Africa from 191 cases per 100,000 in
1990 to 293 in 2000. However, the total number of
new cases will double by the year 2000. Because
of the HIV epidemic, the decline of the crude
incidence rate in the Southeast Asian and
Central and South American regions is expected
to be slower than in previous years. In
industrialized countries, a small increase in
crude incidence rate and total cases is expected as
the result of immigration from countries with a
high prevalence of dual HIV and TB infection.
The worldwide incidence of HIV-attributable
TB cases is estimated to increase from 315,000
(4% of the total TB cases) in 1990 to 1.4 million
(14% of the total TB cases) by the year 2000. In
2000, approximately 40% of these HIV-attribut-
able cases will occur in sub-Saharan Africa and
40% in Southeast Asia. Ten percent of the total
number of TB cases expected during 1990 to 1999
are estimated to be attributable to HIV infection.
While demographic factors, such as popula-
tion growth and changes in population structure,
will largely account for the expected increase in
TB incidence worldwide, the HIV epidemic in
sub-Saharan Africa will have a greater role than
demographic factors.
By the year 2000, 3.5 million persons will be
dying of TB annually, an increase of 39% from
1990. In Southeast Asia alone, 1.4 million deaths
will occur annually. During 1990 to 1999, an
estimated 30 million will die of TB, with 9.7% of the
cases attributable to HIV infection. M. tuberculo-
sis will be largely responsible for the new TB
Table 1. Estimated human tuberculosis and HIV-attributable tuberculosis  cases in 1990, 1995, and 2000, by region (19)
1990 1995 2000
HIV- HIV- HIV-
Region TB cases Ratea attributed TB cases Rate attributed TB cases Rate attributed
Southeast Asia 3,106,000 237   66,000 3,499,000 241 251,000   3,952,000 247    571,000
Western Pacificb 1,839,000 136   19,000 2,045,000 140   31,000   2,255,000 144      68,000
Africa    992,000 191 194,000 1,467,000 242 380,000   2,079,000 293    604,000
Eastern    641,000 165     9,000    745,000 168   16,000      870,000 168      38,000
  Mediterranean
Americasc    569,000 127   20,000    606,000 123   45,000      645,000 120      97,000
Eastern Europed    194,000   47     1,000    202,000   47     2,000      210,000   48        6,000
Industrialized    196,000   23     6,000    204,000   23   13,000      211,000   24      26,000
  countriese
Total TB cases 7,537,000 143 315,000 8,768,000 152 738,000 10,222,000 163 1,410,000
  Attributed to HIV    4.2%     8.4%     13.8%
  Increase since 1990     16.3%       35.6%
aRate: incidence of new cases per 100,000 population.
bWestern Pacific Region of WHO except Japan, Australia, and New Zealand.
cAmerican Region of WHO, except USA and Canada.
dEastern European countries and independent states of the former USSR.
eWestern Europe, USA, Canada, Japan, Australia, and New Zealand.61 Vol. 4, No. 1, January–March 1998 Emerging Infectious Diseases
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cases and deaths, but an unknown, and potentially
important, proportion will be caused by M. bovis.
Bovine TB in Developing Countries
Although prevalence data on animal TB in
developing countries are generally scarce,
information on bovine TB occurrence and control
measures exists (20,21).
Africa
Of 55 African countries, 25 reported sporadic/
low occurrence of bovine TB; six reported enzootic
disease; two, Malawi and Mali, were described as
having a high occurrence; four did not report the
disease; and the remaining 18 countries did not
have data (Figure 1).
Of all nations in Africa, only seven apply
disease control measures as part of a test-and-
slaughter policy and consider bovine TB a
notifiable disease; the remaining 48 control the
disease inadequately or not at all (Figure 2).
Almost 15% of the cattle population are found in
countries where bovine TB is notifiable and a
test-and-slaughter policy is used. Thus, approxi-
mately 85% of the cattle and 82% of the human
population of Africa are in areas where bovine TB
is either partly controlled or not controlled at all.
Asia
Of 36 Asian nations, 16 reported a sporadic/
low occurrence of bovine TB, and one (Bahrain)
described the disease as enzootic; ten did not
report bovine TB; and the remaining nine did not
have data (Figure 3). Within the Asian region,
seven countries apply disease control measures
as part of a test-and-slaughter policy and
consider bovine TB notifiable. In the remaining
29 countries, bovine TB is partly controlled or not
controlled at all (Figure 4).
Of the total Asian cattle and buffalo
populations, 6% and less than 1%, respectively,
are found in countries where bovine TB is
notifiable and a test-and-slaughter policy is used;
94% of the cattle and more than 99% of the
buffalo populations in Asia are either only partly
controlled for bovine TB or not controlled at all.
Thus, 94% of the human population lives in
countries where cattle and buffaloes undergo no
control or only limited control for bovine TB.
Latin American and Caribbean Countries
Of 34 Latin American and Caribbean
countries, 12 reported bovine TB as sporadic/low
occurrence, seven reported it as enzootic, and one
(Dominican Republic) described occurrence as
No data
Not reported
Sporadic
Enzootic
Figure 1. Bovine tuberculosis occurrence, Africa (21).
Not applied
Applied
Figure 2. Control measures for bovine tuberculosis
based on test-and-slaughter policy and disease
notification, Africa (21).62 Emerging Infectious Diseases Vol. 4, No. 1, January–March 1998
Synopses
high. Twelve countries did not report bovine TB.
No data were available for the remaining two
countries (Figure 5).
In the entire region, 12 countries apply disease
control measures as part of a test-and-slaughter
policy and consider bovine TB a notifiable disease.
In the remaining 22 nations, the disease is partly
controlled or not controlled at all (Figure 6). The
regional prevalence of bovine TB has been
estimated at 1% and higher in 67% of the total cattle
population and 0.1% to 0.9% in a further 7%; the
remaining 26% are free of the disease or are
approaching the point of elimination (22).
Of the total Latin American and Caribbean
cattle population, almost 76% is in countries where
bovine TB is notifiable and a test-and-slaughter
Figure 3. Bovine tuberculosis occurrence, Asia (21).
Figure 4. Control measures for bovine tuberculosis
based on test-and-slaughter policy and disease notifi-
cation, Asia (21).
Figure 5. Bovine tuberculosis occurrence, Latin America
and the Caribbean (21).
Figure 6. Control measures for bovine tuberculosis
based on test-and-slaughter policy and disease
notification, Latin America and the Caribbean (21).63 Vol. 4, No. 1, January–March 1998 Emerging Infectious Diseases
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policy is used. Thus, approximately 24% of the
cattle population in this region is either only partly
controlled for bovine TB or not controlled at all. It is
also estimated that 60% of the human population
live in countries where cattle undergo no control or
only limited control for bovine TB.
Zoonotic TB in Humans
TB caused by M. bovis is clinically
indistinguishable from TB caused by M.
tuberculosis. In countries where bovine TB is
uncontrolled, most human cases occur in young
persons and result from drinking or handling
contaminated milk; cervical lymphadenopathy,
intestinal lesions, chronic skin TB (lupus
vulgaris), and other nonpulmonary forms are
particularly common. Such cases may, however,
also be caused by M. tuberculosis. Little is known
of the relative frequency with which M. bovis
causes nonpulmonary TB in developing nations
because of limited laboratory facilities for the
culture and typing of tubercle bacilli.
Agricultural workers may acquire the disease
by inhaling cough spray from infected cattle; they
develop typical pulmonary TB. Such patients
may infect cattle, but evidence for human-to-
human transmission is limited and anecdotal.
In regions where bovine TB has been largely
eliminated, a few residual cases occur among
elderly persons as a result of the reactivation of
dormant lesions. These are fewer than 1% of all
TB cases. Surveys in the United States,
Scandinavia, and South England have shown
that approximately half of these postprimary
cases are pulmonary, a quarter involve the
genitourinary tract (a rare occurrence in primary
disease), and the remainder involve other
nonpulmonary sites, notably cervical lymph
nodes (23). In the same regions, approximately
10% of cases caused by M. tuberculosis are
nonpulmonary, although, for reasons that are not
clear, the incidence is higher, approximately
20%, in ethnic minority populations.
Information on human disease due to M. bovis
in developed and developing countries is scarce.
From a review of a number of zoonotic tuberculosis
studies, published between 1954 and 1970 and
carried out in various countries around the world, it
was estimated that the proportion of human cases
due to M. bovis acccounted for 3.1% of all forms of
tuberculosis: 2.1% of pulmonary forms and 9.4% of
extrapulmonary forms (24).  Table 2 summarizes
the findings of more recent reports of TB caused by
M. bovis in industrialized countries.
Human disease caused by M. bovis has been
confirmed in African countries. In an investiga-
tion by two Egyptian health centers, the
proportions of sputum-positive TB patients
infected with M. bovis, recorded during three
observations, were 0.4%, 6.4%, and 5.4% (33). In
another study in Egypt, nine of 20 randomly
selected patients with TB peritonitis were
infected with M. bovis, and the remaining with
M. tuberculosis (34).
Isolation of M. bovis from sputum samples of
patients with pulmonary TB has also been
reported from Nigeria. Of 102 M. tuberculosis
complex isolates, 4 (3.9%) were M. bovis (35).
Another study in Nigeria reported that one of 10
mycobacteria isolated from sputum-positive
cultures was M. bovis (36).
In a Zaire study, M. bovis was isolated from
gastric secretions in two of five patients with
pulmonary TB (37). In the same study, the
prevalence of the disease in local cattle was
approximately 8% by tuberculin testing and
isolation of M. bovis.
In a recent investigation in Tanzania, seven
of 19 lymph node biopsies from suspected
extrapulmonary TB patients were infected with
M. tuberculosis and four with M. bovis (14). No
mycobacteria were cultured from the remaining
Table 2.  Human tuberculosis due to Mycobacterium
bovis, industrialized countries
Cases
% of Pulmonary
total (% of  total
Country (ref.) Years  No.  TB  M. bovis)
Australia (25) 1970-94 240 0.43-3.1 71.6a
England (23) 1977-90 232 1.2 40.0
Germany (26) 1975-80 236 4.5 73.7
Ireland
  Rural (27) 1986-90   17 6.4 70.6
  Urban (28) 1982-85     9 0.9 88.8
New Zealand (29) 1983-90   22 7.2 31.8
Spain (30) 1986-90   10 0.9 50.0
Sweden (17) 1983-92   96 2.0 -
Switzerland (31) 1994   18 2.6 -
U.S. (32) 1954-68     6 0.3 33.3
U.S. (9) 1980-91   73 3.0 52.0b
12.0c
a Overall percentage includes 80.6 % males  and 51.2%
females.
bAdults.
cChildren.64 Emerging Infectious Diseases Vol. 4, No. 1, January–March 1998
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eight (Table 3). Although the number of samples
was low, the high proportion (36%) of M. bovis
isolates is of serious concern.
In an epidemiologic study in Zambia (38), an
association between tuberculin-positive cattle
and human TB was found. Households that
reported a TB case within the previous 12 months
were approximately seven times more likely to
own herds containing tuberculin-positive cattle
(odds ratio = 7.6; p = 0.004). Although this could
be explained by zoonotic TB transmission, other
factors such as transient sensitivity to tuberculin
of cattle exposed to TB patients and coincidental
environmental factors favoring both human
clinical TB and sensitivity to bovine tuberculin
should also be considered.
In Latin America, a conservative estimate
would be that 2% of the total pulmonary TB cases
and 8% of extrapulmonary TB cases are caused by
M. bovis. These cases would therefore account for
7,000 new TB cases per year, a rate of nearly 2 per
100,000 inhabitants. From a nationwide study in
Argentina during 1982 to 1984, 36 (0.47%) of 7,672
mycobacteria cultured from sputum samples were
M. bovis (39). However, in another study in Santa
Fe province (where most of the dairy cattle industry
is concentrated) during 1984 to 1989, M. bovis
caused 0.7% to 6.2% of TB cases (40).
Very limited data on the zoonotic aspects of
M. bovis are available from Asian countries.
However, cases of TB caused by M. bovis were not
reported in early investigations in India (41).
Epidemiology
Much information on the epidemiologic
patterns of zoonotic TB has been obtained in this
century from industrialized countries. However,
some striking epidemiologic differences related to
both animal and human populations in developing
countries require particular attention.
Risk Factors: Animal Population
Animal reservoirs.  The widespread distribu-
tion of M. bovis in farm and wild animal
populations represents a large reservoir of this
microorganism. The spread of the infection
from affected to susceptible animals in both
industrialized and developing countries is most
likely to occur when wild and domesticated
animals share pasture or territory (42). Well-
documented examples of such spread include
infection in badgers (Meles meles) in the United
Kingdom and possums (Trichosurus vulpecula)
in New Zealand. Wild animal TB represents a
permanent reservoir of infection and poses a
serious threat to control and elimination programs.
Milk production and animal husbandry. Milk
production has increased in most developing
countries as a consequence of greater demand for
milk for human consumption (43; Figure 7). This
increased demand for milk—estimated at 2.5%
per year for 1970 to 1988 for sub-Saharan Africa
(44)—led to increases in the number of productive
animals and milk imports and intensification of
animal production through the introduction of
more productive exotic breeds.
Although the prevalence of the disease within
a country varies from area to area, the highest
incidence of bovine TB is generally observed
Table 3. Isolates from suspected extrapulmonary
tuberculosis patients, Tanzania, 1994 (14)
No.  of M. tuber- M.
Occupation samples culosis bovis Neg.
Livestock   4 0 2 2
  keeper
Farmers   6 2 1 3
Children   3 2 1 0
Unknown   6 3 0 3
Total 19 7 4 8
Figure 7. Cow milk production by region (43).
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where intensive dairy production is most
common, notably in the milksheds of larger cities
(1). This problem is exacerbated where there is
inadequate veterinary supervision, as is the
case in most developing countries. In addition,
in some industrialized countries such as the
United States, where bovine TB is close to
elimination, large dairy herds (i.e., 5,000 or
more cows) that are crowded together repre-
sent the main source of infection (45).
In developing countries, bovine TB infects a
higher proportion of exotic dairy breeds (Bos
taurus) than indigenous zebu cattle (Bos indicus)
and crossbred beef cattle (1). However, under
intensive feedlot conditions, a death rate of 60%
and depression of growth have been found in
tuberculous zebu cattle (46). In those areas where
extensive management is more common, animal
crowding (e.g., near watering ponds, dip tanks,
markets, and corrals) still plays a major role in
the spread of the disease.
Control measures and programs. The basic
strategies required for control and elimination of
bovine TB are well known and well defined (47).
However, because of financial constraints,
scarcity of trained professionals, lack of political
will, as well as the underestimation of the
importance of zoonotic TB in both the animal and
public health sectors by national governments
and donor agencies, control measures are not
applied or are applied inadequately in most
developing countries.
Successful conduct of a test-and-slaughter
policy requires sustained cooperation of national
and private veterinary services, meat inspectors,
and farmers, as well as adequate compensation
for services rendered. Only a few developing
countries can adhere to these requirements.
In addition, bovine TB does not often justify
the emergency measures required for other
zoonotic diseases (e.g., Rinderpest, East Coast
fever, and foot and mouth disease). The full
economic implications of zoonotic TB are,
however, overlooked in many developing nations
where the overall impact of the disease on human
health and animal production needs to be assessed.
According to recent estimates, annual economic
loss to bovine TB in Argentina is approximately 63
million US dollars (48). In a study recently
conducted in Turkey, the estimated socioeconomic
impact of bovine TB to both the agriculture and
health sectors was approximately 15 to 59 million
US dollars per year (49).
Several Latin American countries, through
agreements between governments and cattle
owners associations, have made the decision to
control and eliminate bovine TB. Where foot and
mouth disease has been eliminated, bovine TB
and other existing infections such as brucellosis
become important because of their impact on the
meat and live animal export trade. Bovine TB and
brucellosis also limit the development of the dairy
industry and its expansion at the regional level.
Risk Factors: Human Population
Close physical contact. Close physical
contact between humans and potentially infected
animals is present in some communities,
especially in developing regions. For example, in
many African countries cattle are an integral
part of human social life; they represent wealth
and are at the center of many events and,
therefore, gatherings. In addition, with 65% of
African, 70% of Asian, and 26% of Latin American
and Caribbean populations working in agricul-
ture, a significant proportion of the population of
these regions may be at risk for bovine TB.
Food hygiene practices. Consumption of
milk contaminated by M. bovis has long been
regarded as the principal mode of TB transmis-
sion from animals to humans (1). In regions
where bovine TB is common and uncontrolled,
milkborne infection is the principal cause of
cervical lymphadenopathy (scrofula) and ab-
dominal and other forms of nonpulmonary TB.
Although proper food hygiene practices could
play a major role in controlling these forms of TB,
such practices are often difficult to institute in
developing countries.
In all countries of sub-Saharan Africa, there
is active competition between large-scale, often
state-run, processing and marketing enterprises
and the informal sector. The informal sector can
ignore standards of hygiene and quality, and
producers often sell directly to the final
consumers. In addition, an estimated 90% of the
total milk produced is consumed fresh or soured
(44). Although it has been stated that Africans
generally boil milk and that the souring process
destroys  M. bovis (44), other sources strongly
contradict these statements (39). M. bovis was66 Emerging Infectious Diseases Vol. 4, No. 1, January–March 1998
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isolated from seven (2.9%) of 241 samples of raw
milk in Ethiopia (17). Both M. bovis and
M. tuberculosis have also been found in milk
samples in Nigeria (36) and Egypt (34). Thus,
serious public health implications of poten-
tially contaminated milk and milk products
should not be underestimated.
HIV/AIDS. According to recent WHO global
estimates, of the 9.4 million people infected with
both HIV and TB in mid-1996, 6.6 million (70%)
live in sub-Saharan Africa (4). The greatest
impact of HIV infection on TB is in populations
with a high prevalence of TB infection among
young adults. The occurrence of both infections in
one person makes TB infection very likely to
progress to active disease.
In many developing countries, TB is the most
frequent opportunistic disease associated with
HIV infection. HIV seroprevalence rates greater
than 60% have been found in TB patients in
various African countries (4). Persons infected
with both pathogens have an annual risk of
progression to active TB of 5% to 15%, depending on
their level of immunosuppression; approximately
10% of non-HIV infected persons newly infected
with TB become ill at some time during their lives.
In the remaining 90%, effective host defenses
prevent progression from infection to disease.
TB cases due to M. bovis in HIV-positive
persons also resemble disease caused by
M. tuberculosis. Thus, they manifest as
pulmonary disease, lymphadenopathy, or, in
the more profoundly immunosuppressed, dis-
seminated disease.
M. bovis has been isolated from HIV-infected
persons in industrialized countries. In France, M.
bovis infection accounted for 1.6% of TB cases in
HIV-positive patients. All isolated strains were
resistant to isoniazid (7). Taking into consider-
ation the intrinsic resistance of M. bovis to
pyrazinamide, two of the first-line anti-TB drugs
were not effective. WHO-recommended standard
treatment for new TB cases includes, in the initial
phase, isoniazid, rifampicin, pyrazinamide, and
streptomycin or ethambutol. In situations of high
primary resistance to isoniazid and streptomy-
cin, the intrinsic resistance of M. bovis to
pyrazinamide may severely limit the efficacy of
treatment of TB caused by M. bovis.
In a Paris hospital, a source patient with
pulmonary TB due to a multidrug-resistant
strain of M. bovis led to active disease in five
patients. Disease occurred 3 to 10 months after
infection (10). This observation led to three
concerns: 1) human-to-human M. bovis transmis-
sion leading to overt disease, 2) a short interval
between infection and overt disease, and 3)
disseminated multidrug-resistant M. bovis.
In another study, conducted in San Diego,
California, one of 24 adults with pulmonary TB and
11 of 24 adults with nonpulmonary TB due to M.
bovis had AIDS. One of 25 children, a 16-year-old
boy with abdominal TB, was also HIV-positive (9).
It is commonly believed that M. bovis is less
virulent than M. tuberculosis in humans and
therefore less likely to lead to overt postprimary
disease and that human-to-human transmission
leading to infectious disease is rare. However, if
the apparent difference in virulence is the result
of differences in responsiveness of the host
defense mechanisms, HIV-induced immunosup-
pression could well lower host defenses leading to
overt disease after infection.
Surveillance of TB due to M. bovis
The use of direct smear microscopy as the
only method for diagnosis of suspected TB,
although an essential requirement of any
national TB program, could partly explain the
relatively low notification rate of disease caused
by M. bovis in developing countries. Direct smear
microscopy does not permit differentiation
between species of the M. tuberculosis complex;
in addition, culture and speciation are often not
carried out, and even when culture facilities are
available,  M. bovis grows poorly in standard
Löwenstein-Jensen medium, one of the most
widely used culture media (50). In some
countries, human disease caused by M. bovis is
merely reported as TB to avoid inquiries from
disease control agencies, which might generate
problems of patient confidentiality (2).
The collection of representative data on the
incidence of TB due to M. bovis from most
laboratories in developing countries has addi-
tional problems. For example, the location and
coverage of laboratories are often biased towards
city populations; sputum specimens may pre-
dominate, with relatively few specimens from
extrapulmonary lesions, particularly among
children. Specimens from children with TB are
frequently negative on culture, and biopsies are
difficult to take from lesions.
Recent outbreaks of multidrug-resistant TB
in some parts of the world underscore the need for67 Vol. 4, No. 1, January–March 1998 Emerging Infectious Diseases
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surveillance through wider application of reliable
culture and drug susceptibility tests.
Control Measures and Programs in
Developing Countries
Bovine TB can be eliminated from a country
or region by implementing a test-and-slaughter
policy, if no other reservoir host of infection
exists. While the test-and-slaughter policy is
likely to remain the backbone of national
elimination bovine TB programs, the policy has
numerous constraints in developing countries.
Alternative strategies (e.g., programs based on
slaughterhouse surveillance and traceback of
tuberculous animals to herds of origin) may be
technically and economically more appropriate in
these countries.
Measures to prevent transmission of infection
should be the primary objective to be achieved with
trained public health personnel, public education,
and proper hygienic practices. Test-and-slaughter
programs may be feasible and appropriate in areas
with low bovine TB prevalence and effective control
of animal movement.
Animal Vaccination and Research
Developments
Although not usually considered relevant to
elimination programs in livestock (47), vaccination
of animals against TB would be a viable strategy in
two disease control situations: in domesticated
animals in developing countries and in wildlife and
feral reservoirs of disease in industrialized
countries where test-and-slaughter programs have
failed to achieve elimination of the disease.
Many issues need to be addressed before
vaccination becomes a realistic option for control
of disease in cattle and other animals. First, a
highly effective vaccine needs to be developed.
The results obtained globally with bacillus
Calmette-Guérin (BCG) have been suboptimal,
and efficacy has varied considerably from region
to region (42,51). Secondly, the delivery of the
vaccine poses few problems in domesticated
animals, but it is fraught with difficulties in wild
animals. Thirdly, vaccination may compromise
diagnostic tests. A vaccine that induces tubercu-
lin reactivity would invalidate the key diagnostic
tool used in control programs. Fourthly, short of
performing lengthy and expansive field studies,
evaluation of the protective efficacy of a new
vaccine will pose serious difficulties. Tradition-
ally, the guinea pig and mouse have been used for
this purpose, but the information gained has been
of little value. Recent work has, however,
indicated that deer may well prove a suitable
mammal for evaluating new vaccines and
optimum delivery systems (52).
Enzyme-linked immunosorbent assay and
gamma-interferon tests may prove to be more
sensitive and specific than the tuberculin test and
may facilitate diagnostic procedures. Nucleic
acid-based technology, notably polymerase chain
reaction and related methods, may provide more
rapid, sensitive, and specific diagnostic tools.
Multicenter studies of the applicability of these
techniques to the diagnosis of human TB have,
however, shown that their sensitivity and
specificity are not as high as originally expected
and that many problems need to be solved before
the techniques are introduced into routine
laboratory practice (53). Restriction fragment
length polymorphism analysis (DNA fingerprint-
ing) could be useful in epidemiologic studies that
trace the spread of disease between cattle, other
animals, and humans (54) or in the rapid
differentiation of M. bovis within the M.
tuberculosis complex (55). The use of these
techniques is limited by resources in most
developing countries.
WHO and Zoonotic TB
The public health importance of animal TB
was recognized early by WHO, which in its 1950
report of the Expert Committee on Tuberculosis
(56) stated: “The committee recognizes the
seriousness of human infection with bovine
tuberculosis in countries where the disease in
cattle is prevalent. There is the danger of
transmission of infection by direct contact
between diseased cattle and farm workers and
their families, as well as from infected food
products.” Since then, TB in animals has been
controlled and almost eliminated in several
industrialized countries but in very few
developing countries.
More recently, WHO has been involved in
zoonotic TB through the activities of the Division
of Emerging and other Communicable Diseases
Surveillance and Control at WHO in Geneva
(WHO/EMC) and the Veterinary Public Health
program of the WHO Regional Office for the
Americas, Pan American Health Organization
(PAHO/HCV).
WHO/EMC has organized and coordinated a
working group of experts from countries68 Emerging Infectious Diseases Vol. 4, No. 1, January–March 1998
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worldwide (15-17). Their subjects are epidemiol-
ogy, public health aspects, control, and research
on zoonotic TB. In addition, a joint WHO, Food
and Agriculture Organization of the United
Nations (FAO), and Office International des
Epizooties (OIE) Consultation on Animal Tuber-
culosis Vaccines was held to review current
knowledge on TB vaccine development for
humans and animals and make recommenda-
tions for animal TB vaccine research and
development (57). Promising results of cattle
vaccination with low doses of BCG were reported.
It is also planned for field trial cattle vaccination
to commence early in 1998 in Madagascar in
collaboration with national and international
research institutions, OIE and WHO. In the
framework of the working group activities, the
guidelines for speciation within the Mycobacte-
rium tuberculosis complex (50) have been
prepared to respond to the growing need for
reliable differentiation between M. tuberculosis,
M. africanum, and M. bovis and to promote and
strengthen surveillance.
A Plan of Action for the Eradication of Bovine
Tuberculosis in the Americas (18) has been
developed by PAHO in collaboration with
member countries of the region. PAHO/HCV, in
cooperation with the Pan American Institute for
Food Protection and Zoonosis (INPPAZ), Buenos
Aires, Argentina, and other technical institutions
(e.g., FAO), provides technical support to the
regional plan. PAHO/HCV activities train
specialists in diagnosis, reporting, surveillance
systems, and quality control of reagents, as well
as supporting the planning and implementation
of national programs. INPPAZ acts as a reference
center for these activities. The first phase of the
regional plan is expected to lead, in the next 10
years, to the elimination of bovine TB from
countries with more advanced national pro-
grams. In the remaining countries, the objectives
will be to strengthen epidemiologic surveillance,
defining areas at risk and setting up control and
elimination programs.
Conclusions
Although the epidemiology of bovine TB is
well understood and effective control and
elimination strategies have been known for a long
time, the disease is still widely distributed and
often neglected in most developing countries. Its
public health consequences, although well
documented from the past experiences of
industrialized countries, have scarcely been
investigated and are still largely ignored in these
regions. Because of the animal and public health
consequences of M. bovis, disease surveillance
programs in humans should be considered a
priority, especially in areas where risk factors
are present. The increase of TB in such areas
calls for stronger intersectoral collaboration
between the medical and veterinary profes-
sions to assess and evaluate the scale of the
problem, mostly when zoonotic TB could
represent a significant risk, for example, in
rural communities and in the workplace.
Industrialized countries, where the test-and-
slaughter policies have not completely elimi-
nated infection in cattle because of wild animal
reservoirs, are now reconsidering wild animal
vaccination. Any vaccination research and
development program should therefore also take
into account the possible application of vaccines
to cattle, particularly in developing countries.
In developing countries, where HIV and
bovine TB are likely to be common, particularly in
young persons, the ability of HIV infection to
abrogate any host factors that prevent the
progression of infection by M. bovis to overt
disease may lead to higher incidence and case-
fatality rates for human TB caused by this species
and increased human-to-human transmission of
this disease. This should be of great concern in
those developing countries where bovine TB is
present and measures to control spread of
infection are not applied or are applied
inadequately. Research is needed to determine
when  M. bovis is of zoonotic importance and what
the underlying mechanisms of transmission are.
Locally operative risk factors for zoonotic TB
should therefore be identified to determine
persons at risk and develop appropriate control
measures. International cooperation in all
aspects of zoonotic TB remains essential in the
fight against this disease.
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